ct-3

ACT-389949 is a potent and selective agonist of formyl peptide receptor type 2 (FPR2) Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2 ALX internalization into monocytes. It has the potential for the treatment of inflammatory disorders.

ACT-387042 is a Bacterial Topoisomerase Inhibitor, it has broad-spectrum activity against Gram-positive and Gram-negative bacteria.

ACT-373898 is a metabolite of the endothelin (ET) receptor type A (ETA) and ETBdual antagonist macitentan .1 1.Dingemanse, J., Sidharta, P.N., Maddrey, W.C., et al.Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertensionExpert Opin. Drug Saf.13(3)391-405(2013)

5-Allyl-3-methoxy-6-methyl-7-(3,4,5-trimethoxyphenyl)bicyclo[3.2.1]oct-3-ene-2,8-dione is a natural product for research related to life sciences. The catalog number is TN3104 and the CAS number is 106894-43-3.

CHIR-99021 (CT99021) is an activator of the Wnt β-catenin signaling pathway and a GSK-3α β inhibitor (IC50=10 6.7 nM) with selective and oral activity.CHIR-99021 induces cellular autophagy, which enhances self-renewal in mouse and human embryonic stem cells.

Marizomib is a novel irreversible brain-permeable proteasome inhibitor that inhibits CT-L (β5), CT-T-laspase-like (C-L, β1), and trypsin-like (T-L, β2) 20S proteasomes with IC50s of 3.5, 28, and 430 nM.[3]

Tandutinib (CT53518) (MLN518, CT53518), an effective FLT3 antagonist (IC50: 0.22 μM), can also inhibit c-Kit and PDGFR, 15-20 fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR, and KDR.

MAGL-IN-20 (compound ±34) is a reversible inhibitor of monoacylglycerol lipase (MAGL). It exhibits significant antiproliferative activity against a range of cancer cell lines, including H460, HT29, CT-26, Huh7, and HCCLM-3.

CHIR-98014 (CT98014) is a selective GSK3 inhibitor; potentiate insulin activation of glucose transport and utilization in vitro and in vivo.

Combretastatin A-1 is a potent microtubule inhibitor with anti-tumour and anti-vascular activity, acting through microtubule protein depolymerisation-mediated inactivation of AKT to inhibit the Wnt β-catenin pathway, and can be used to study hepatocellular carcinoma.

Firivumab (CT-P22; CT120), a human IgG1 monoclonal antibody targeting influenza A virus hemagglutinin (Anti-IAV HA), demonstrates neutralization capabilities against multiple strains including H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2, and H12N7. It has also shown to protect mice from the H1N1 virus [1] [2] [3].

Pegdinetanib (BMS-844203; CT-322) is a selective inhibitor targeting VEGFR-2 (VEGFR), with dissociation constants (Kd) of 11 nM and 250 nM and half-maximal inhibitory concentrations (IC50) of 16 nM and 240 nM for human and murine VEGFR-2, respectively, and shows no affinity for VEGFR-1 or VEGFR-3, demonstrating antitumor activity [1].

Laduviglusib [CHIR 99021; CHIR99021; CHIR-99021; CT99021; CT 99021; CT-99021] is a potent, selective small-molecule inhibitor of glycogen synthase kinase 3 (GSK-3) with the formula C22H18ClN5O. It is used extensively in biomedical research to explore the role of GSK-3 in various cellular processes and diseases.

CT-08 (CT8, Compound 3) is a macrolide Sec61 modulator that inhibits protein secretion in a signal sequence-dependent manner. It prevents the Sec61-mediated translocation of VCAMss-GLuc to the ER, resulting in the loss of luciferase activity. Additionally, CT-08 suppresses the expression of VCAM in transfected cells.